Skip to main content
NCBI home page
Postgraduate Medical Journal logoLink to Postgraduate Medical Journal
. 1994 Dec;70(830):863–870. doi: 10.1136/pgmj.70.830.863

Corticosteroids: do they damage the cardiovascular system?

S R Maxwell 1, R J Moots 1, M J Kendall 1
PMCID: PMC2398024  PMID: 7870631

Abstract

Since their introduction for the treatment of rheumatoid arthritis, corticosteroids have become widely used as effective agents in the control of inflammatory diseases. Although there have been undoubted benefits upon mortality in diseases such as systemic lupus erythematosus, many patients survive only to suffer a high incidence of premature atherosclerosis. There is also evidence of increased rates of vascular mortality in other corticosteroid-treated diseases, such as rheumatoid arthritis, reversible airways obstruction and transplant recipients. Possible mechanisms of damage include elevated blood pressure, impaired glucose tolerance, dyslipidaemia, and imbalances in thrombosis and fibrinolysis. This paper reviews the clinical evidence supporting the contention that there is an excess cardiovascular mortality in steroid-treated patients and the underlying mechanisms, and points to further areas of research.

Full text

PDF
863

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. ADLERSBERG D., SCHAEFER L., DRACHMAN S. R. Development of hypercholesteremia during cortisone and ACTH therapy. J Am Med Assoc. 1950 Nov 11;144(11):909–914. doi: 10.1001/jama.1950.02920110021006. [DOI] [PubMed] [Google Scholar]
  2. Abeles M., Urman J. D., Rothfield N. F. Aseptic necrosis of bone in systemic lupus erythematosus. Relationship to corticosteroid therapy. Arch Intern Med. 1978 May;138(5):750–754. [PubMed] [Google Scholar]
  3. Allebeck P. Increased mortality in rheumatoid arthritis. Scand J Rheumatol. 1982;11(2):81–86. doi: 10.3109/03009748209098167. [DOI] [PubMed] [Google Scholar]
  4. Aqel N. M., Ball R. Y., Waldmann H., Mitchinson M. J. Monocytic origin of foam cells in human atherosclerotic plaques. Atherosclerosis. 1984 Dec;53(3):265–271. doi: 10.1016/0021-9150(84)90127-8. [DOI] [PubMed] [Google Scholar]
  5. Asakura Y., Nakamoto S., Nishikawa Y., Abe S., Handa S., Konishi K., Yamada T., Hattori S. [A case of myocardial infarction in a young man with systemic lupus erythematosus]. Kokyu To Junkan. 1992 May;40(5):495–498. [PubMed] [Google Scholar]
  6. Bagdade J. D., Porte D., Jr, Bierman E. L. Steroid-induced lipemia. A complication of high-dosage corticosteroid therapy. Arch Intern Med. 1970 Jan;125(1):129–134. doi: 10.1001/archinte.125.1.129. [DOI] [PubMed] [Google Scholar]
  7. Becker D. M., Chamberlain B., Swank R., Hegewald M. G., Girardet R., Baughman K. L., Kwiterovich P. O., Pearson T. A., Ettinger W. H., Renlund D. Relationship between corticosteroid exposure and plasma lipid levels in heart transplant recipients. Am J Med. 1988 Nov;85(5):632–638. doi: 10.1016/s0002-9343(88)80234-1. [DOI] [PubMed] [Google Scholar]
  8. Berdanier C. D. Role of glucocorticoids in the regulation of lipogenesis. FASEB J. 1989 Aug;3(10):2179–2183. doi: 10.1096/fasebj.3.10.2666232. [DOI] [PubMed] [Google Scholar]
  9. Bergstein J. M., Wiens C., Fish A. J., Vernier R. L., Michael A. Avascular necrosis of bone in systemic lupus erythematosus. J Pediatr. 1974 Jul;85(1):31–35. doi: 10.1016/s0022-3476(74)80281-7. [DOI] [PubMed] [Google Scholar]
  10. Blackwell G. J., Carnuccio R., Di Rosa M., Flower R. J., Parente L., Persico P. Macrocortin: a polypeptide causing the anti-phospholipase effect of glucocorticoids. Nature. 1980 Sep 11;287(5778):147–149. doi: 10.1038/287147a0. [DOI] [PubMed] [Google Scholar]
  11. Boettcher W. G., Bonfiglio M., Hamilton H. H., Sheets R. F., Smith K. Non-traumatic necrosis of the femoral head. I. Relation of altered hemostasis to etiology. J Bone Joint Surg Am. 1970 Mar;52(2):312–321. [PubMed] [Google Scholar]
  12. Brooks P. M., Stephens W. H., Jr, Stephens M. E., Buchanan W. W. How safe are anti-rheumatic drugs? A study of possible iatrogenic deaths in patients with rheumatoid arthritis. Health Bull (Edinb) 1975 May;33(3):108–111. [PubMed] [Google Scholar]
  13. Bruce B. K., King B. M., Phelps G. R., Veitia M. C. Effects of adrenalectomy and corticosterone administration on hypothalamic obesity in rats. Am J Physiol. 1982 Aug;243(2):E152–E157. doi: 10.1152/ajpendo.1982.243.2.E152. [DOI] [PubMed] [Google Scholar]
  14. Bulkley B. H., Roberts W. C. The heart in systemic lupus erythematosus and the changes induced in it by corticosteroid therapy. A study of 36 necropsy patients. Am J Med. 1975 Feb;58(2):243–264. doi: 10.1016/0002-9343(75)90575-6. [DOI] [PubMed] [Google Scholar]
  15. Burke G. L., Webber L. S., Srinivasan S. R., Radhakrishnamurthy B., Freedman D. S., Berenson G. S. Fasting plasma glucose and insulin levels and their relationship to cardiovascular risk factors in children: Bogalusa Heart Study. Metabolism. 1986 May;35(5):441–446. doi: 10.1016/0026-0495(86)90135-6. [DOI] [PubMed] [Google Scholar]
  16. COPEMAN W. S. C., SAVAGE O., BISHOP P. M. F., DODDS E. C., GOTTLIEB B., GLYN J. H. H., HENLY A. A., KELLIE A. E. A study of cortisone and other steroids in rheumatoid arthritis. Br Med J. 1950 Oct 14;2(4684):849–855. doi: 10.1136/bmj.2.4684.849. [DOI] [PMC free article] [PubMed] [Google Scholar]
  17. COSGRIFF S. W. Thromboembolic complications associated with ACTH and cortisone therapy. J Am Med Assoc. 1951 Nov 3;147(10):924–926. doi: 10.1001/jama.1951.03670270014006. [DOI] [PubMed] [Google Scholar]
  18. Cain G. D., Mayer G., Jones E. A. Augmentation of albumin but not fibrinogen synthesis by corticosteroids in patients with hepatocellular disease. J Clin Invest. 1970 Dec;49(12):2198–2204. doi: 10.1172/JCI106438. [DOI] [PMC free article] [PubMed] [Google Scholar]
  19. Chan L., O'Malley B. W. Mechanism of action of the sex steroid hormones (second of three parts). N Engl J Med. 1976 Jun 17;294(25):1372–1381. doi: 10.1056/NEJM197606172942505. [DOI] [PubMed] [Google Scholar]
  20. Conn D. L., Tompkins R. B., Nichols W. L. Glucocorticoids in the management of vasculitis--a double edged sword? J Rheumatol. 1988 Aug;15(8):1181–1183. [PubMed] [Google Scholar]
  21. Crane L. J., Miller D. L. Plasma protein synthesis by isolated rat hepatocytes. J Cell Biol. 1977 Jan;72(1):11–25. doi: 10.1083/jcb.72.1.11. [DOI] [PMC free article] [PubMed] [Google Scholar]
  22. Donahue R. P., Abbott R. D., Bloom E., Reed D. M., Yano K. Central obesity and coronary heart disease in men. Lancet. 1987 Apr 11;1(8537):821–824. doi: 10.1016/s0140-6736(87)91605-9. [DOI] [PubMed] [Google Scholar]
  23. Ducimetiere P., Eschwege E., Papoz L., Richard J. L., Claude J. R., Rosselin G. Relationship of plasma insulin levels to the incidence of myocardial infarction and coronary heart disease mortality in a middle-aged population. Diabetologia. 1980 Sep;19(3):205–210. doi: 10.1007/BF00275270. [DOI] [PubMed] [Google Scholar]
  24. Ducimetiere P., Richard J., Cambien F. The pattern of subcutaneous fat distribution in middle-aged men and the risk of coronary heart disease: the Paris Prospective Study. Int J Obes. 1986;10(3):229–240. [PubMed] [Google Scholar]
  25. Ettinger W. H., Jr, Hazzard W. R. Elevated apolipoprotein-B levels in corticosteroid-treated patients with systemic lupus erythematosus. J Clin Endocrinol Metab. 1988 Sep;67(3):425–428. doi: 10.1210/jcem-67-3-425. [DOI] [PubMed] [Google Scholar]
  26. Ettinger W. H., Klinefelter H. F., Kwiterovitch P. O. Effect of short-term, low-dose corticosteroids on plasma lipoprotein lipids. Atherosclerosis. 1987 Feb;63(2-3):167–172. doi: 10.1016/0021-9150(87)90117-1. [DOI] [PubMed] [Google Scholar]
  27. FROESCH E. R., WINEGRAD A. I., RENOLD A. E., THORN G. W. Mechanism of the glucosuria produced by the administration of steroids with glucocorticoid activity. J Clin Invest. 1958 Apr;37(4):524–532. doi: 10.1172/JCI103634. [DOI] [PMC free article] [PubMed] [Google Scholar]
  28. Fisher D. E., Bickel W. H. Corticosteroid-induced avascular necrosis. A clinical study of seventy-seven patients. J Bone Joint Surg Am. 1971 Jul;53(5):859–873. [PubMed] [Google Scholar]
  29. Fisher D. E., Bickel W. H., Holley K. E. Histologic demonstration of fat emboli in aseptic necrosis associated with hypercortisonism. Mayo Clin Proc. 1969 Apr;44(4):252–259. [PubMed] [Google Scholar]
  30. Fisher D. E. The role of fat embolism in the etiology of corticosteroid-induced avascular necrosis: clinical and experimental results. Clin Orthop Relat Res. 1978 Jan-Feb;(130):68–80. [PubMed] [Google Scholar]
  31. Flier J. S., Kahn C. R., Roth J. Receptors, antireceptor antibodies and mechanisms of insulin resistance. N Engl J Med. 1979 Feb 22;300(8):413–419. doi: 10.1056/NEJM197902223000808. [DOI] [PubMed] [Google Scholar]
  32. Flower R. J., Blackwell G. J. Anti-inflammatory steroids induce biosynthesis of a phospholipase A2 inhibitor which prevents prostaglandin generation. Nature. 1979 Mar 29;278(5703):456–459. doi: 10.1038/278456a0. [DOI] [PubMed] [Google Scholar]
  33. Foster C. J., Weinsier R. L., Birch R., Norris D. J., Bernstein R. S., Wang J., Pierson R. N., Van Itallie T. B. Obesity and serum lipids: an evaluation of the relative contribution of body fat and fat distribution to lipid levels. Int J Obes. 1987;11(2):151–161. [PubMed] [Google Scholar]
  34. Ginzler E. M., Diamond H. S., Weiner M., Schlesinger M., Fries J. F., Wasner C., Medsger T. A., Jr, Ziegler G., Klippel J. H., Hadler N. M. A multicenter study of outcome in systemic lupus erythematosus. I. Entry variables as predictors of prognosis. Arthritis Rheum. 1982 Jun;25(6):601–611. doi: 10.1002/art.1780250601. [DOI] [PubMed] [Google Scholar]
  35. Ginzler E., Berg A. Mortality in systemic lupus erythematosus. J Rheumatol Suppl. 1987 Jun;14 (Suppl 13):218–222. [PubMed] [Google Scholar]
  36. Gladman D. D., Urowitz M. B. Morbidity in systemic lupus erythematosus. J Rheumatol Suppl. 1987 Jun;14 (Suppl 13):223–226. [PubMed] [Google Scholar]
  37. Goldfine I. D., Kahn C. R., Neville D. M., Jr, Roth J., Garrison M. M., Bates R. W. Decreased binding of insulin to its receptors in rats with hormone induced insulin resistance. Biochem Biophys Res Commun. 1973 Aug 6;53(3):852–857. doi: 10.1016/0006-291x(73)90171-x. [DOI] [PubMed] [Google Scholar]
  38. Goldie I., Tibblin G., Scheller S. Systemic lupus erythematosus (SLE) and aseptic bone necrosis. A discussion based on the presentation of one case treated with corticosteroids. Acta Med Scand. 1967 Jul;182(1):55–63. [PubMed] [Google Scholar]
  39. Granelli-Piperno A., Vassalli J. D., Reich E. Secretion of plasminogen activator by human polymorphonuclear leukocytes. Modulation by glucocorticoids and other effectors. J Exp Med. 1977 Dec 1;146(6):1693–1706. doi: 10.1084/jem.146.6.1693. [DOI] [PMC free article] [PubMed] [Google Scholar]
  40. Grieninger G., Hertzberg K. M., Pindyck J. Fibrinogen synthesis in serum-free hepatocyte cultures: stimulation by glucocorticoids. Proc Natl Acad Sci U S A. 1978 Nov;75(11):5506–5510. doi: 10.1073/pnas.75.11.5506. [DOI] [PMC free article] [PubMed] [Google Scholar]
  41. Gustafsson J. A., Carlstedt-Duke J., Poellinger L., Okret S., Wikström A. C., Brönnegård M., Gillner M., Dong Y., Fuxe K., Cintra A. Biochemistry, molecular biology, and physiology of the glucocorticoid receptor. Endocr Rev. 1987 May;8(2):185–234. doi: 10.1210/edrv-8-2-185. [DOI] [PubMed] [Google Scholar]
  42. Haffner S. M., Fong D., Hazuda H. P., Pugh J. A., Patterson J. K. Hyperinsulinemia, upper body adiposity, and cardiovascular risk factors in non-diabetics. Metabolism. 1988 Apr;37(4):338–345. doi: 10.1016/0026-0495(88)90133-3. [DOI] [PubMed] [Google Scholar]
  43. Hartz A. J., Rupley D. C., Rimm A. A. The association of girth measurements with disease in 32,856 women. Am J Epidemiol. 1984 Jan;119(1):71–80. doi: 10.1093/oxfordjournals.aje.a113727. [DOI] [PubMed] [Google Scholar]
  44. Hirata F., Notsu Y., Yamada R., Ishihara Y., Wano Y., Kunos I., Kunos G. Isolation and characterization of lipocortin (lipomodulin). Agents Actions. 1986 Jan;17(3-4):263–266. doi: 10.1007/BF01982617. [DOI] [PubMed] [Google Scholar]
  45. Hollifield G. Glucocorticoid-induced obesity--a model and a challenge. Am J Clin Nutr. 1968 Dec;21(12):1471–1474. doi: 10.1093/ajcn/21.12.1471. [DOI] [PubMed] [Google Scholar]
  46. Homcy C. J., Liberthson R. R., Fallon J. T., Gross S., Miller L. M. Ischemic heart disease in systemic lupus erythematosus in the young patient: report of six cases. Am J Cardiol. 1982 Feb 1;49(2):478–484. doi: 10.1016/0002-9149(82)90528-8. [DOI] [PubMed] [Google Scholar]
  47. Horber F. F., Zürcher R. M., Herren H., Crivelli M. A., Robotti G., Frey F. J. Altered body fat distribution in patients with glucocorticoid treatment and in patients on long-term dialysis. Am J Clin Nutr. 1986 May;43(5):758–769. doi: 10.1093/ajcn/43.5.758. [DOI] [PubMed] [Google Scholar]
  48. Hurley R. M., Steinberg R. H., Patriquin H., Drummond K. N. A vascular necrosis of the femoral head in childhood systemic lupus erythematosus. Can Med Assoc J. 1974 Oct 19;111(8):781–784. [PMC free article] [PubMed] [Google Scholar]
  49. Ichikawa Y., Toguchi T., Kawagoe M., Saito E., Abe T., Homma M. E.C.G. abnormalities in steroid-treated rheumatoid patients. Lancet. 1977 Oct 15;2(8042):828–828. doi: 10.1016/s0140-6736(77)90767-x. [DOI] [PubMed] [Google Scholar]
  50. Jackson S. H., Beevers D. G., Myers K. Does long-term low-dose corticosteroid therapy cause hypertension? Clin Sci (Lond) 1981 Dec;61 (Suppl 7):381s–383s. doi: 10.1042/cs061381s. [DOI] [PubMed] [Google Scholar]
  51. Jeejeebhoy K. N., Bruce-Robertson A., Ho J., Sodtke U. The effect of cortisol on the synthesis of rat plasma albumin, fibrinogen and transferrin. Biochem J. 1972 Nov;130(2):533–538. doi: 10.1042/bj1300533. [DOI] [PMC free article] [PubMed] [Google Scholar]
  52. Jensen G., Sigurd B. Systemic lupus erythematosus and acute myocardial infarction. Chest. 1973 Nov;64(5):653–654. doi: 10.1378/chest.64.5.653. [DOI] [PubMed] [Google Scholar]
  53. John D. W., Miller L. L. Regulation of net biosynthesis of serum albumin and acute phase plasma proteins. Induction of enhanced net synthesis of fibrinogen, alpha1-acid glycoprotein, alpha2 (acute phase)-globulin, and haptoglobin by amino acids and hormones during perfusion of the isolated normal rat liver. J Biol Chem. 1969 Nov 25;244(22):6134–6142. [PubMed] [Google Scholar]
  54. Jonsson H., Nived O., Sturfelt G. Outcome in systemic lupus erythematosus: a prospective study of patients from a defined population. Medicine (Baltimore) 1989 May;68(3):141–150. [PubMed] [Google Scholar]
  55. Kalbak K. Incidence of arteriosclerosis in patients with rheumatoid arthritis receiving long-term corticosteroid therapy. Ann Rheum Dis. 1972 May;31(3):196–200. doi: 10.1136/ard.31.3.196. [DOI] [PMC free article] [PubMed] [Google Scholar]
  56. Kalimi M., Colman P., Feigelson P. The "activated" hepatic glucocorticoid-receptor complex. Its generation and properties. J Biol Chem. 1975 Feb 10;250(3):1080–1086. [PubMed] [Google Scholar]
  57. Kannel W. B., Wolf P. A., Castelli W. P., D'Agostino R. B. Fibrinogen and risk of cardiovascular disease. The Framingham Study. JAMA. 1987 Sep 4;258(9):1183–1186. [PubMed] [Google Scholar]
  58. Kaplan N. M. The deadly quartet. Upper-body obesity, glucose intolerance, hypertriglyceridemia, and hypertension. Arch Intern Med. 1989 Jul;149(7):1514–1520. doi: 10.1001/archinte.149.7.1514. [DOI] [PubMed] [Google Scholar]
  59. Karsh J., Klippel J. H., Balow J. E., Decker J. L. Mortality in lupus nephritis. Arthritis Rheum. 1979 Jul;22(7):764–769. doi: 10.1002/art.1780220712. [DOI] [PubMed] [Google Scholar]
  60. Keen H. Glucose intolerance, diabetes mellitus and atherosclerosis; prospects for prevention. Postgrad Med J. 1976 Jul;52(609):445–451. doi: 10.1136/pgmj.52.609.445. [DOI] [PMC free article] [PubMed] [Google Scholar]
  61. Krakoff L. R. Glucocorticoid excess syndromes causing hypertension. Cardiol Clin. 1988 Nov;6(4):537–545. [PubMed] [Google Scholar]
  62. Krotkiewski M., Björntorp P., Sjöström L., Smith U. Impact of obesity on metabolism in men and women. Importance of regional adipose tissue distribution. J Clin Invest. 1983 Sep;72(3):1150–1162. doi: 10.1172/JCI111040. [DOI] [PMC free article] [PubMed] [Google Scholar]
  63. Lapidus L., Bengtsson C., Larsson B., Pennert K., Rybo E., Sjöström L. Distribution of adipose tissue and risk of cardiovascular disease and death: a 12 year follow up of participants in the population study of women in Gothenburg, Sweden. Br Med J (Clin Res Ed) 1984 Nov 10;289(6454):1257–1261. doi: 10.1136/bmj.289.6454.1257. [DOI] [PMC free article] [PubMed] [Google Scholar]
  64. Larsson B., Svärdsudd K., Welin L., Wilhelmsen L., Björntorp P., Tibblin G. Abdominal adipose tissue distribution, obesity, and risk of cardiovascular disease and death: 13 year follow up of participants in the study of men born in 1913. Br Med J (Clin Res Ed) 1984 May 12;288(6428):1401–1404. doi: 10.1136/bmj.288.6428.1401. [DOI] [PMC free article] [PubMed] [Google Scholar]
  65. Lewis G. D., Campbell W. B., Johnson A. R. Inhibition of prostaglandin synthesis by glucocorticoids in human endothelial cells. Endocrinology. 1986 Jul;119(1):62–69. doi: 10.1210/endo-119-1-62. [DOI] [PubMed] [Google Scholar]
  66. MERRELL M., SHULMAN L. E. Determination of prognosis in chronic disease, illustrated by systemic lupus erythematosus. J Chronic Dis. 1955 Jan;1(1):12–32. doi: 10.1016/0021-9681(55)90018-7. [DOI] [PubMed] [Google Scholar]
  67. Meade T. W., Mellows S., Brozovic M., Miller G. J., Chakrabarti R. R., North W. R., Haines A. P., Stirling Y., Imeson J. D., Thompson S. G. Haemostatic function and ischaemic heart disease: principal results of the Northwick Park Heart Study. Lancet. 1986 Sep 6;2(8506):533–537. doi: 10.1016/s0140-6736(86)90111-x. [DOI] [PubMed] [Google Scholar]
  68. Meade T. W., North W. R., Chakrabarti R., Stirling Y., Haines A. P., Thompson S. G., Brozovié M. Haemostatic function and cardiovascular death: early results of a prospective study. Lancet. 1980 May 17;1(8177):1050–1054. doi: 10.1016/s0140-6736(80)91498-1. [DOI] [PubMed] [Google Scholar]
  69. Mejia G., Zimmerman S. W., Glass N. R., Miller D. T., Sollinger H. W., Belzer F. O. Renal transplantation in patients with systemic lupus erythematosus. Arch Intern Med. 1983 Nov;143(11):2089–2092. [PubMed] [Google Scholar]
  70. Meller J., Conde C. A., Deppisch L. M., Donoso E., Dack S. Myocardial infarction due to coronary atherosclerosis in three young adults with systemic lupus erythematosus. Am J Cardiol. 1975 Feb;35(2):309–314. doi: 10.1016/0002-9149(75)90019-3. [DOI] [PubMed] [Google Scholar]
  71. Moncada S., Vane J. R. Pharmacology and endogenous roles of prostaglandin endoperoxides, thromboxane A2, and prostacyclin. Pharmacol Rev. 1978 Sep;30(3):293–331. [PubMed] [Google Scholar]
  72. Monson R. R., Hall A. P. Mortality among arthritics. J Chronic Dis. 1976 Jul;29(7):459–467. doi: 10.1016/0021-9681(76)90086-2. [DOI] [PubMed] [Google Scholar]
  73. Mutru O., Laakso M., Isomäki H., Koota K. Ten year mortality and causes of death in patients with rheumatoid arthritis. Br Med J (Clin Res Ed) 1985 Jun 15;290(6484):1797–1799. doi: 10.1136/bmj.290.6484.1797. [DOI] [PMC free article] [PubMed] [Google Scholar]
  74. Myles A. Corticosteroid treatment in rheumatoid arthritis. Br J Rheumatol. 1985 May;24(2):125–127. doi: 10.1093/rheumatology/24.2.125. [DOI] [PubMed] [Google Scholar]
  75. Orchard T. J., Becker D. J., Bates M., Kuller L. H., Drash A. L. Plasma insulin and lipoprotein concentrations: an atherogenic association? Am J Epidemiol. 1983 Sep;118(3):326–337. doi: 10.1093/oxfordjournals.aje.a113639. [DOI] [PubMed] [Google Scholar]
  76. Parrillo J. E., Fauci A. S. Mechanisms of glucocorticoid action on immune processes. Annu Rev Pharmacol Toxicol. 1979;19:179–201. doi: 10.1146/annurev.pa.19.040179.001143. [DOI] [PubMed] [Google Scholar]
  77. Peiris A. N., Mueller R. A., Smith G. A., Struve M. F., Kissebah A. H. Splanchnic insulin metabolism in obesity. Influence of body fat distribution. J Clin Invest. 1986 Dec;78(6):1648–1657. doi: 10.1172/JCI112758. [DOI] [PMC free article] [PubMed] [Google Scholar]
  78. Peiris A. N., Sothmann M. S., Hoffmann R. G., Hennes M. I., Wilson C. R., Gustafson A. B., Kissebah A. H. Adiposity, fat distribution, and cardiovascular risk. Ann Intern Med. 1989 Jun 1;110(11):867–872. doi: 10.7326/0003-4819-110-11-867. [DOI] [PubMed] [Google Scholar]
  79. Princen H. M., Moshage H. J., de Haard H. J., van Gemert P. J., Yap S. H. The influence of glucocorticoid on the fibrinogen messenger RNA content of rat liver in vivo and in hepatocyte suspension culture. Biochem J. 1984 Jun 15;220(3):631–637. doi: 10.1042/bj2200631. [DOI] [PMC free article] [PubMed] [Google Scholar]
  80. Prior P., Symmons D. P., Scott D. L., Brown R., Hawkins C. F. Cause of death in rheumatoid arthritis. Br J Rheumatol. 1984 May;23(2):92–99. doi: 10.1093/rheumatology/23.2.92. [DOI] [PubMed] [Google Scholar]
  81. Pyöräla K. Relationship of glucose tolerance and plasma insulin to the incidence of coronary heart disease: results from two population studies in Finland. Diabetes Care. 1979 Mar-Apr;2(2):131–141. doi: 10.2337/diacare.2.2.131. [DOI] [PubMed] [Google Scholar]
  82. ROSENFELD S., MARMORSTON J., SOBEL H., WHITE A. E. Enhancement of experimental atherosclerosis by ACTH in the dog. Proc Soc Exp Biol Med. 1960 Jan;103:83–86. doi: 10.3181/00379727-103-25420. [DOI] [PubMed] [Google Scholar]
  83. Rasker J. J., Cosh J. A. Cause and age at death in a prospective study of 100 patients with rheumatoid arthritis. Ann Rheum Dis. 1981 Apr;40(2):115–120. doi: 10.1136/ard.40.2.115. [DOI] [PMC free article] [PubMed] [Google Scholar]
  84. Reilly P. A., Cosh J. A., Maddison P. J., Rasker J. J., Silman A. J. Mortality and survival in rheumatoid arthritis: a 25 year prospective study of 100 patients. Ann Rheum Dis. 1990 Jun;49(6):363–369. doi: 10.1136/ard.49.6.363. [DOI] [PMC free article] [PubMed] [Google Scholar]
  85. Rinehart J. J., Balcerzak S. P., Sagone A. L., LoBuglio A. F. Effects of corticosteroids on human monocyte function. J Clin Invest. 1974 Dec;54(6):1337–1343. doi: 10.1172/JCI107880. [DOI] [PMC free article] [PubMed] [Google Scholar]
  86. Rinehart J. J., Sagone A. L., Balcerzak S. P., Ackerman G. A., LoBuglio A. F. Effects of corticosteroid therapy on human monocyte function. N Engl J Med. 1975 Jan 30;292(5):236–241. doi: 10.1056/NEJM197501302920504. [DOI] [PubMed] [Google Scholar]
  87. Robinette C. D., Fraumeni J. F., Jr Asthma and subsequent mortality in World War II veterans. J Chronic Dis. 1978;31(9-10):619–624. doi: 10.1016/0021-9681(78)90022-x. [DOI] [PubMed] [Google Scholar]
  88. Rosenfeld M. E., Tsukada T., Gown A. M., Ross R. Fatty streak initiation in Watanabe Heritable Hyperlipemic and comparably hypercholesterolemic fat-fed rabbits. Arteriosclerosis. 1987 Jan-Feb;7(1):9–23. doi: 10.1161/01.atv.7.1.9. [DOI] [PubMed] [Google Scholar]
  89. SAVAGE O., COPEMAN W. S., CHAPMAN L., WELLS M. V., TREADWELL B. L. Pituitary and adrenal hormones in rheumatoid arthritis. Lancet. 1962 Feb 3;1(7223):232–235. doi: 10.1016/s0140-6736(62)91186-8. [DOI] [PubMed] [Google Scholar]
  90. Sandercock P. A., Warlow C. P., Jones L. N., Starkey I. R. Predisposing factors for cerebral infarction: the Oxfordshire community stroke project. BMJ. 1989 Jan 14;298(6666):75–80. doi: 10.1136/bmj.298.6666.75. [DOI] [PMC free article] [PubMed] [Google Scholar]
  91. Scott D. L., Symmons D. P., Coulton B. L., Popert A. J. Long-term outcome of treating rheumatoid arthritis: results after 20 years. Lancet. 1987 May 16;1(8542):1108–1111. doi: 10.1016/s0140-6736(87)91672-2. [DOI] [PubMed] [Google Scholar]
  92. Smyllie H. C., Connolly C. K. Incidence of serious complications of corticosteroid therapy in respiratory disease. A retrospective survey of patients in the Brompton hospital. Thorax. 1968 Nov;23(6):571–581. doi: 10.1136/thx.23.6.571. [DOI] [PMC free article] [PubMed] [Google Scholar]
  93. Stone M. C., Thorp J. M. Plasma fibrinogen--a major coronary risk factor. J R Coll Gen Pract. 1985 Dec;35(281):565–569. [PMC free article] [PubMed] [Google Scholar]
  94. Strain G. W., Zumoff B., Strain J. J., Levin J., Fukushima D. K. Cortisol production in obesity. Metabolism. 1980 Oct;29(10):980–985. doi: 10.1016/0026-0495(80)90043-8. [DOI] [PubMed] [Google Scholar]
  95. TREADWELL B. L., SEVER E. D., SAVAGE O., COPEMAN W. S. SIDE-EFFECTS OF LONG-TERM TREATMENT WITH CORTICOSTEROIDS AND CORTICOTROPHIN. Lancet. 1964 May 23;1(7343):1121–1123. doi: 10.1016/s0140-6736(64)91804-5. [DOI] [PubMed] [Google Scholar]
  96. Tanaka K., Masuda J., Imamura T., Sueishi K., Nakashima T., Sakurai I., Shozawa T., Hosoda Y., Yoshida Y., Nishiyama Y. A nation-wide study of atherosclerosis in infants, children and young adults in Japan. Atherosclerosis. 1988 Aug;72(2-3):143–156. doi: 10.1016/0021-9150(88)90075-5. [DOI] [PubMed] [Google Scholar]
  97. Thomas T. P. The complications of systemic corticosteroid therapy in the elderly. A retrospective study. Gerontology. 1984;30(1):60–65. doi: 10.1159/000212608. [DOI] [PubMed] [Google Scholar]
  98. Thong K. L., Mant M. J., Grace M. G. Lack of effect of prednisone administration on bleeding time and platelet function of normal subjects. Br J Haematol. 1978 Mar;38(3):373–380. doi: 10.1111/j.1365-2141.1978.tb01057.x. [DOI] [PubMed] [Google Scholar]
  99. Tsakraklides V. G., Blieden L. C., Edwards J. E. Coronary atherosclerosis and myocardial infarction associated with systemic lupus erythematosus. Am Heart J. 1974 May;87(5):637–641. doi: 10.1016/0002-8703(74)90504-3. [DOI] [PubMed] [Google Scholar]
  100. Urowitz M. B., Bookman A. A., Koehler B. E., Gordon D. A., Smythe H. A., Ogryzlo M. A. The bimodal mortality pattern of systemic lupus erythematosus. Am J Med. 1976 Feb;60(2):221–225. doi: 10.1016/0002-9343(76)90431-9. [DOI] [PubMed] [Google Scholar]
  101. Vassalli J. D., Hamilton J., Reich E. Macrophage plasminogen activator: modulation of enzyme production by anti-inflammatory steroids, mitotic inhibitors, and cyclic nucleotides. Cell. 1976 Jun;8(2):271–281. doi: 10.1016/0092-8674(76)90011-8. [DOI] [PubMed] [Google Scholar]
  102. Welborn T. A., Wearne K. Coronary heart disease incidence and cardiovascular mortality in Busselton with reference to glucose and insulin concentrations. Diabetes Care. 1979 Mar-Apr;2(2):154–160. doi: 10.2337/diacare.2.2.154. [DOI] [PubMed] [Google Scholar]
  103. Wilhelmsen L., Svärdsudd K., Korsan-Bengtsen K., Larsson B., Welin L., Tibblin G. Fibrinogen as a risk factor for stroke and myocardial infarction. N Engl J Med. 1984 Aug 23;311(8):501–505. doi: 10.1056/NEJM198408233110804. [DOI] [PubMed] [Google Scholar]
  104. Wing R. R., Bunker C. H., Kuller L. H., Matthews K. A. Insulin, body mass index, and cardiovascular risk factors in premenopausal women. Arteriosclerosis. 1989 Jul-Aug;9(4):479–484. doi: 10.1161/01.atv.9.4.479. [DOI] [PubMed] [Google Scholar]
  105. Yukimura Y., Bray G. A., Wolfsen A. R. Some effects of adrenalectomy in the fatty rat. Endocrinology. 1978 Nov;103(5):1924–1928. doi: 10.1210/endo-103-5-1924. [DOI] [PubMed] [Google Scholar]
  106. Zimmerman J., Fainaru M., Eisenberg S. The effects of prednisone therapy on plasma lipoproteins and apolipoproteins: a prospective study. Metabolism. 1984 Jun;33(6):521–526. doi: 10.1016/0026-0495(84)90006-4. [DOI] [PubMed] [Google Scholar]
  107. Zizic T. M., Marcoux C., Hungerford D. S., Dansereau J. V., Stevens M. B. Corticosteroid therapy associated with ischemic necrosis of bone in systemic lupus erythematosus. Am J Med. 1985 Nov;79(5):596–604. doi: 10.1016/0002-9343(85)90057-9. [DOI] [PubMed] [Google Scholar]

Articles from Postgraduate Medical Journal are provided here courtesy of BMJ Publishing Group

RESOURCES